Aug 5, 4:50 PM ET
Novanta reported second quarter 2026 results for the period ended July 3, 2026, with GAAP revenue up 10% to $266 million and GAAP net income of $12.5 million, compared with $4.5 million a year earlier. The company also updated its third quarter and full year 2026 guidance to include the recently closed Riverpoint Medical acquisition, which it says roughly doubles its recurring medical consumables business.
- GAAP diluted EPS was $0.30 versus $0.12 a year earlier; Adjusted Diluted EPS rose 17.1% to $0.89.
- Adjusted EBITDA rose 16.4% to $60.7 million, with an Adjusted EBITDA margin of 22.8%.
- Q3 2026 guidance: GAAP revenue of $300 million to $304 million and Adjusted Diluted EPS of $0.95 to $1.00.
- Full year 2026 guidance: GAAP revenue of $1,130 million to $1,140 million and Adjusted Diluted EPS of $3.68 to $3.74.
Read the filing on SEC.gov ↗
Jul 27, 8:15 AM ET
Novanta completed its acquisition of Riverpoint Medical on July 23, 2026, paying the seller approximately $1.2 billion in cash, subject to customary adjustments, with a further $250.0 million milestone payment due by January 8, 2027. The company funded the deal by borrowing $616.0 million under its credit facilities and using cash on hand, bringing consolidated debt to $854.7 million as of July 22, 2026. The company expects the deal to add $0.18 to $0.25 of adjusted earnings per share in 2027, its first full year after closing.
- Closed July 23, 2026, with approximately $1.2 billion paid in cash at closing
- $250.0 million milestone payment remains payable to the seller on or before January 8, 2027
- $616.0 million borrowed under revolving and delayed draw term loan facilities; consolidated debt $854.7 million as of July 22, 2026
- Expected to contribute $0.18 to $0.25 of adjusted EPS in 2027; 2026 impact to be discussed on the second quarter earnings call
Read the filing on SEC.gov ↗
Jun 9, 5:00 PM ET
Novanta agreed on June 8, 2026 to sell 2,142,857 common shares at $140.00 each in a private placement to institutional and accredited investors, for an aggregate purchase price of approximately $300.0 million before placement agent fees and expenses. The closing is expected on June 11, 2026, subject to customary conditions, and the company agreed to register the resale of the shares, which would add to the share count for existing holders.
- Purchase price: $140.00 per share, 2,142,857 shares, about $300.0 million aggregate
- Expected closing on or about June 11, 2026, subject to customary closing conditions
- Post-closing count: 42,473,345 common shares outstanding or issuable under Tangible Equity Units, based on 35,613,303 shares outstanding as of June 8, 2026
- Registration statement due within 30 days after closing; placement agents include J.P. Morgan Securities LLC and PNC Capital Markets LLC
Read the filing on SEC.gov ↗
Jun 9, 6:02 AM ET
Novanta agreed on June 8, 2026 to acquire Riverpoint Medical from Arlington Capital Partners for $1.2 billion in cash at closing, plus a $250 million milestone payment due by January 8, 2027. The deal is funded with cash on hand, existing credit facilities and a $300 million equity raise, and the credit agreement was amended to raise the permitted leverage ratio, which means more debt for shareholders to carry. The company expects the deal to close in the third quarter of 2026 and says it will update guidance after closing.
- Purchase price of $1.2 billion in cash at closing, subject to customary adjustments, plus a $250 million milestone payment due on or before January 8, 2027
- Financing from cash on hand, existing credit facilities and a recently completed $300 million equity raise
- Credit agreement amended: permitted consolidated leverage ratio raised to 4.00 to 1.00, or 4.50 to 1.00 for four quarters after a designated acquisition
- Expected net leverage of about 2.7x at closing in the third quarter of 2026, with a target below 2.3x by year-end 2027; standalone 2026 guidance was confirmed
Read the filing on SEC.gov ↗
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.